Media coverage about Novartis AG (NYSE:NVS) has trended somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis AG earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.9802032154455 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Novartis AG (NVS) Upgraded to Hold at BidaskClub (americanbankingnews.com)
- Why a typically blasé event is a big deal for this Peninsula biotech (bizjournals.com)
- Buy Novartis Under $80 – Cramer’s Lightning Round (8/17/17) (seekingalpha.com)
- The FDA Just Approved a New Pfizer Cancer Drug for a Rare, Vicious Leukemia (finance.yahoo.com)
- Recent MYL News (bloomberg.com)
NVS has been the topic of a number of recent analyst reports. Vetr lowered Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 price target on the stock. in a report on Tuesday, April 25th. Zacks Investment Research raised Novartis AG from a “strong sell” rating to a “hold” rating in a research report on Monday, May 1st. UBS AG reissued a “neutral” rating on shares of Novartis AG in a research report on Wednesday, May 24th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a research report on Friday, June 2nd. Finally, Morgan Stanley reissued a “sell” rating on shares of Novartis AG in a research report on Tuesday, June 6th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $83.56.
Shares of Novartis AG (NYSE:NVS) traded down 0.50% during midday trading on Friday, reaching $82.76. The company’s stock had a trading volume of 1,319,136 shares. The company’s 50-day moving average price is $83.92 and its 200-day moving average price is $79.10. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The company has a market cap of $193.90 billion, a PE ratio of 30.22 and a beta of 0.73.
Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.23 EPS. On average, equities analysts anticipate that Novartis AG will post $4.73 EPS for the current fiscal year.
In other Novartis AG news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of Novartis AG stock in a transaction on Wednesday, July 5th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.01% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Novartis AG (NVS) Given News Sentiment Score of 0.16” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-novartis-ag-nvs-share-price-updated-updated-updated.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.